Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Collaborative Study on the Classification of Silicone Oil Droplets and Protein Particles Using Flow Imaging Method.
Shibata H, Terabe M, Shibano Y, Saitoh S, Takasugi T, Hayashi Y, Okabe S, Yamaguchi Y, Yasukawa H, Suetomo H, Miyanabe K, Ohbayashi N, Akimaru M, Saito S, Ito D, Nakano A, Kojima S, Miyahara Y, Sasaki K, Maruno T, Noda M, Kiyoshi M, Harazono A, Torisu T, Uchiyama S, Ishii-Watabe A. Shibata H, et al. Among authors: terabe m. J Pharm Sci. 2022 Oct;111(10):2745-2757. doi: 10.1016/j.xphs.2022.07.006. Epub 2022 Jul 14. J Pharm Sci. 2022. PMID: 35839866 Free article.
Preface: NKT Cells for Tumor Immunotherapy.
Terabe M, Kumar V. Terabe M, et al. Crit Rev Oncog. 2024;29(1):ix-x. doi: 10.1615/CritRevOncog.2023050202. Crit Rev Oncog. 2024. PMID: 38421709 No abstract available.
Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response.
Stirling ER, Terabe M, Wilson AS, Kooshki M, Yamaleyeva LM, Alexander-Miller MA, Zhang W, Miller LD, Triozzi PL, Soto-Pantoja DR. Stirling ER, et al. Among authors: terabe m. J Immunother Cancer. 2022 Nov;10(11):e004712. doi: 10.1136/jitc-2022-004712. J Immunother Cancer. 2022. PMID: 36418073 Free PMC article.
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy.
Maeng HM, Moore BN, Bagheri H, Steinberg SM, Inglefield J, Dunham K, Wei WZ, Morris JC, Terabe M, England LC, Roberson B, Rosing D, Sachdev V, Pack SD, Miettinen MM, Barr FG, Weiner LM, Panch S, Stroncek DF, Wood LV, Berzofsky JA. Maeng HM, et al. Among authors: terabe m. Front Oncol. 2021 Dec 16;11:789078. doi: 10.3389/fonc.2021.789078. eCollection 2021. Front Oncol. 2021. PMID: 34976830 Free PMC article.
124 results